Dr. Evgeny Zaytsev
Director
Board of Director
Novadigm
Russian Federation
Biography
Dr. Evgeny Zaytsev is a venture capitalist with more than twelve years’ investment experience in life sciences. Before joining RMI Partners (the management company for RusnanoMedInvest) he was a general partner at Helix Ventures (Palo Alto, California), which he co-founded to exclusively invest in novel therapeutic opportunities (biopharmaceuticals and medical devices). Prior to Helix Dr. Zaytsev was a partner of the venture capital pioneer Pitch Johnson at Asset Management Company, one of the oldest venture firms in Silicon Valley. Dr. Zaytsev has been involved in more than 30 investments in biomedical companies, including such success stories of venture capital as BiPar Sciences (acquired by sanofi-aventis), Chimerix (NADSDAQ: CMRX), Enteric Medical Technologies (acquired by Boston Scientific), Fusion Medical Technologies (acquired by Baxter International), MicroVention (acquired by Terumo Corporation), TriVascular (acquired by Boston Scientific). He has been a Board Member of a number of companies in Silicon Valley and Russia. Evgeny Zaytsev has been Chief Scientific Officer of Institute of Medico-Ecological Problems in Barnaul, Siberia, Russia, responsible for studying the health and environmental effects of the former Soviet Union's nuclear tests. Under his leadership the Institute developed into an internationally recognized research center. Dr. Zaytsev is an active business community leader, a founder and the first president of US-Russia Technology Symposium at Stanford University (now Global Technology Symposium), and the annual Silicon Valley Open Doors investment conference. Dr. Zaytsev is an author of more than 70 scientific and business publications on entrepreneurship, venture capital and biotechnology. Evgeny Zaytsev received his M.D. (cum laude) in 1991 and his Ph.D. in physiology in 1993, both from the Altai State Medical University. He earned his M.B.A. from the Stanford Graduate School of Business in 2002.
Research Interest
Medical Technologies, Molecular biology
